Acamprosate prevents relapse to drinking in alcoholism

Sep 08, 2010

Acamprosate reduces the number of patients being treated for alcoholism who return to drinking, according to a new Cochrane Systematic Review. The drug showed moderate benefits in trials when used in addition to non-drug treatments.

Drinking too much alcohol increases the risk of ill health. According to the , is at the root of around a quarter of all cases of oesophageal cancer, and epilepsy, as well as road accidents and homicides. Acamprosate and are drugs used alongside psychosocial methods to help prevent relapse in alcoholics who are trying to stop .

The researchers reviewed data from 24 randomised controlled trials, considered the gold standard for clinical studies. Altogether these trials involved 6,915 alcohol dependent patients who were also undergoing psychosocial therapies. Acamprosate prevented relapse in one in every nine patients who had stopped drinking and increased the number of days patients spent not drinking by an average of three days a month. The researchers showed that the risk of a patient on acamprosate returning to drinking was 86% of that of a patient who took a placebo instead. was the only side effect that was more frequently reported under acamprosate than placebo.

"Acamprosate is certainly no magic bullet, but it is a safe and effective treatment for patients who are trying to stop drinking," said lead researcher Susanne Rösner of the Psychiatric Hospital at the University of Munich, Germany. "The benefits we have seen in these trials are small. However, we must remember that these are additional benefits on top of those from other non-drug therapies."

The researchers stress the need to respect a patient's right to choose by providing all the necessary information about the benefits and drawbacks of the drugs when recommending a therapeutic strategy. "Patients' doubts and reservations against a strategy that uses one substance to treat dependency on another should be taken seriously, while interventions that have been shown to work should not kept back from patients," said Rösner.

Explore further: Lilly psoriasis drug fares well in late-stage test

add to favorites email to friend print save as pdf

Related Stories

Drug has potential to prevent alcoholics from relapsing

Jul 30, 2008

An experimental drug that blocks the euphoric feelings associated with drinking may prevent alcoholics from relapsing. The finding, the result of a mouse study at Oregon Health & Science University, could lead to human clinical ...

Excessive drinking and relapse rapidly cut in new approach

Jun 09, 2008

Boosting the level of a specific brain protein quickly cut excessive drinking of alcohol in a new animal study, and also prevented relapse -- the common tendency found in sober alcoholics to easily return to heavy drinking ...

Mayo Clinic seeks new therapies for alcoholic hepatitis

Dec 01, 2008

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study ...

Recommended for you

Lilly psoriasis drug fares well in late-stage test

23 minutes ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

13 hours ago

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Shootist
not rated yet Sep 08, 2010
Acamprosate prevented relapse in one in every nine patients who had stopped drinking


Which is about the recovery rate with no assistance at all.